The European Medicines Agency believes that the benefits of its emergency use far outweigh the risks.
The EU is following in the footsteps of the US and Pfizer will have the first approved serum for children
The European Medicines Agency (EMA) has authorized this Thursday emergency use From Vaccination against him COVID-19 developed by laboratories pfizer,biontech In children between 5 and 11 years old, Which can be used first in this age group with The European Union (The European Union). Twenty-seven follow in view of this America who had already authorized the use of this serum for the little ones at the end of October. According to the conclusion of the EMA, the vaccine is safe and effective and will be administered in two injections Of 10 micrograms in the arm, a third is given to people over 12 years of age (30 mcg), with an interval between both of three weeks.
As explained by the EMA, the main study conducted in nearly 2,000 children between the ages of 5 and 11 showed that an immune response with Dosage Lower in this age group is compared with doses given to people aged 16 to 25 and in this group “the benefits outweigh the risks, especially in conditions that increase the risk of severe COVID19“. are” although the EMA will continue to be closely monitored as they are used in vaccination campaigns.
NS Side effects They are also similar to those seen in people over the age of 12 and include injection site pain, fatigue, headache, redness and swelling at the injection site, muscle aches, and chills. These effects are usually mild or moderate and improve within a few days of vaccination. As recommended by the EMA, Joe continues to evaluate the use of Modern Serum (spikewax) for children 6 to 11 years of age, the vaccine contains a 90.7% effectiveness in preventing symptomatic covid19 Although the actual rate may be between 67.7 and 98.3%.
in the footsteps of the united states
The first country to authorize the use of Pfizer Serum in children ages 5 to 11 was the United States on October 29. According to the Food and Drug Administration (FDA), the immune response of children in this age group is comparable to that of youth between the ages of 16 and 25 and was 90.7% effective in the prevention of 19.Covid.
Regarding the safety of the vaccine, it was tested in 3,100 children and serious side effects were ruled out. However, clinical studies on populations of 4,700 children are ongoing in the United States, Finland, Poland, and Spain. 39% of cases till the end of October coronavirus Those under the age of 18 corresponded to an age group of 5 to 11 years. In addition, 8,300 children in this age group had to be hospitalized and by 17 October, 146 had died.
Expanding Pfizer’s vaccine coverage is part of a campaign launched in recent days by European regulators, the European Center for Disease Prevention and Control (ECDC), and the European Center for Disease Prevention and Control (ECDC). The European Commission To make citizens aware of the need for vaccination, in the case of those who have not yet done so, and to receive a booster dose for those who have already completed the regimen. “current level Vaccination In the EU it will be insufficient to limit the burden of covid19 cases and hospitalization during the winter months and countries with low vaccination rates are at greater risk”, the ECDC director warned on Thursday, Andrea Ammon, ,
Until now, the general slogan was to offer a booster dose to the elderly or those with weakened immune systems, although the EMA already acknowledged last week that “sooner or later” normalize the booster dose to “restore and rdquor”. Will happen; After completing the guideline you get the level of security. with him Infection again widespread in most of Europe and a epidemiological situation This forcefully worsens, with the European Union now recommending that governments begin injecting a third dose to all adults over the age of 40.
For now, the European regulator has authorized the use of booster doses from pharmaceutical companies Pfizer and Modern For and assesses those over the age of 18 astraZeneca And Janssen However, there is no date for the conclusion of the study. European Commission President Ursula von der Leyen warned: “Booster doses increase the level of protection even above the basic vaccination. They prevent many hospitalizations and deaths.” Despite the fact that the delta version, the dominant one in Europe, is 60% more permeable than the original.